What Is Porphyria Cutanea Tarda
Porphyria cutanea tarda (PCT) is the most common hepatic porphyria, characterized by fragile skin and blistering photosensitivity due to uroporphyrinogen decarboxylase (UROD) deficiency. In PCT, low-level enzyme impairment leads to accumulation of porphyrins—especially uroporphyrin—in the liver and plasma, causing oxidative damage when exposed to sunlight. It typically presents in adults with painless blisters on sun-exposed areas, hypertrichosis, and scleroderma-like changes on the hands. Two forms exist: sporadic (type 1), driven by UROD inhibition from factors like iron overload, and familial (type 2), caused by heterozygous UROD mutations. Understanding this distinction is central to risk stratification, treatment, and USMLE-style reasoning about porphyrias.
Key Pathophysiology and USMLE-Relevant Biochemistry
The Heme Biosynthetic Block in PCT
PCT is a disorder of heme biosynthesis at the level of UROD, the enzyme that converts uroporphyrinogen III to coproporphyrinogen III. This step is inhibited by factors that either reduce enzyme activity (UROD mutations in type 2) or increase substrate drive and oxidative stress (iron overload in type 1). The resulting accumulation of uroporphyrin and other carboxylated porphyrins causes photosensitivity because these molecules react with oxygen upon light absorption, generating reactive oxygen species that damage skin cells. In contrast to acute hepatic porphyrias, PCT lacks significant neurovisceral attacks, a distinction frequently tested on the USMLE. Recognizing this pattern helps differentiate PCT from variegate porphyria and hereditary coproporphyria when answering clinical vignettes.
Clinical Features and Physical Exam Findings
Photosensitivity is the hallmark, typically beginning subtly with facial erythema and pruritus after sun exposure. Over time, fragile skin leads to erosions and blisters on the dorsa of the hands, forearms, and face, often with minimal trauma. Healing frequently leaves atrophic scars and milia. Hypertrichosis—coarse dark hair on the temples and malar regions—is common in adults and a useful distinguishing feature. A characteristic finding is the presence of pink-red urine that darkens on standing (due to porphyrin oxidation). In longstanding disease, scleroderma-like changes, including skin tightening on the hands, can develop. These clinical cues, when paired with age and risk factors such as alcohol or estrogen use, guide appropriate testing in a USMLE-format case.
Diagnostic Evaluation and Tests
Diagnosis of PCT is confirmed by demonstrating elevated levels of uroporphyrin and heptacarboxyl porphyrin in plasma, urine, and feces, along with specific findings on ancillary testing. Initial screening often begins with a 24-hour urine porphyrins profile, revealing a characteristic pattern of markedly elevated uroporphyrin I and III. Fecal porphyrins are also elevated, with a predominance of isocoproporphyrin. Measurement of UROD enzyme activity in red blood cells or hepatocytes can confirm reduced enzyme function, though this is less commonly performed in routine care. HCV coinfection and HFE gene mutation testing are recommended because they are prevalent associations. A concise summary of key diagnostic markers is provided in the table below for quick review and test-prep purposes.
| Attribute | Verified Detail | Source Type |
|---|---|---|
| Primary accumulating porphyrin | Uroporphyrin I and III (urine and plasma) | Laboratory reference |
| Urine appearance | Pink-red, darkening on standing | Clinical observation |
| Fecal isocoproporphyrin | Elevated | Laboratory reference |
| UROD enzyme activity | Reduced in affected individuals | Functional assay |
| Common cofactors/associations | Iron overload, HCV infection, HFE mutations | Clinical guidelines |
Management and Treatment Overview
Management of PCT centers on reducing porphyrin burden and addressing modifiable triggers. First-line therapy involves gradual phlebotomy to remove iron stores, typically aiming to induce iron depletion until serum ferritin reaches approximately 20–60 mcg/L; this reduces substrate availability for UROD inhibition and often leads to substantial clinical improvement. Alternatively, low-dose hydroxychloroquine can be used, particularly in patients who cannot tolerate phlebotomy, as it facilitates porphyrin excretion via the liver. Avoidance of alcohol, estrogen, and other liver stressors is advised. Sun protection with physical barriers and broad-spectrum sunscreens is essential to prevent lesions. In refractory cases, combined approaches may be considered. Monitoring involves periodic assessment of symptoms, porphyrin levels, and iron studies to guide therapy and prevent complications related to iron depletion.
Differential Diagnosis and USMLE Distinctions
When answering clinical vignettes, it is important to distinguish PCT from other porphyrias. Acute hepatic porphyrias (acute intermittent porphyria, hereditary coproporphyria, variegate porphyria) present with neurovisceral attacks and may have cutaneous manifestations only in the porphyrias that produce photosensitivity. Variegate porphyria and hereditary coproporphyria can feature both abdominal pain and photosensitivity, whereas PCT presents with prominent skin fragility and blistering without acute attacks. Within the category of cutaneous photosensitivity disorders, PCT must also be differentiated from erythropoietic protoporphyria and other porphyrias by pattern of porphyrin elevation and enzyme profiling. These distinctions are commonly tested in the USMLE and are best approached by integrating clinical phenotype with laboratory findings.
Prognosis, Comorbidities, and Long-Term Considerations
With appropriate management, PCT prognosis is generally favorable, though skin changes may persist if diagnosis and treatment are delayed. Recurrence is possible if iron stores are replenished or triggers such as alcohol or estrogen are reintroduced. Because PCT is strongly associated with HCV infection and HFE-related iron overload, screening and treatment of these comorbidities are important parts of comprehensive care. Long-term follow-up should include monitoring for iron depletion after phlebotomy and periodic evaluation of porphyrin levels to ensure biochemical control. These points highlight the value of integrating metabolic insights with systemic risk factor management, a theme frequently emphasized in USMLE-style case-based reasoning.
High-Yield Points for USMLE Preparation
- PCT is the most common hepatic porphyria; typically presents in adulthood with blistering photosensitivity and hypertrichosis.
- Key biochemical finding: elevated uroporphyrin I and III in urine, plasma, and stool due to UROD deficiency.
- Two forms: sporadic (type 1, acquired UROD inhibition) and familial (type 2, heterozygous UROD mutation).
- Common cofactors: iron overload, hepatitis C virus infection, alcohol, estrogen use, and smoking.
- First-line treatments: therapeutic phlebotomy or oral hydroxychloroquine; sun protection is essential.
- Urine may appear pink-red and darken on standing due to porphyrin oxidation.
Bottom Line
Porphyria cutanea tarda is a treatable hepatic porphyria characterized by uroporphyrin accumulation, photosensitive skin fragility, and distinct biochemical patterns. Recognition of risk factors, high-yield clinical features, and laboratory abnormalities facilitates accurate diagnosis and effective management. For USMLE preparation, focus on the phenotype–biochemistry relationship, key associations, and therapy principles to confidently approach both standalone and integrated vignettes.